² National Center for Health Statistics. Health, United States, 2019: Table 21. Hyattsville, MD. 2021. Available from: https://www.cdc.gov/nchs/hus/data-finder.htm

³ https://www.webmd.com/diet/ss/slideshow-five-percent-weight-loss

*Estimated weight loss based on a randomized clinical study¹ of adults with obesity or overweight (with at least one weight-related condition). Average starting weight of participants was 233 lbs. People with diabetes were excluded. Over 68 weeks, significantly more adults lost 5% (12 lbs) to 15% (35 lbs) of body weight when given once-weekly injections of Wegovy (semaglutide), compared to those not treated, who lost an average of 2.5% body weight (6 lbs). Both study groups were also guided to increase physical activity and follow a reduced calorie diet. Other GLP-1s or related medications for weight loss or improved blood sugar control for diabetes (eg, Ozempic, Saxenda, Mounjaro) are also effective at long-term weight loss in some people. Your results may vary.

**The price of a subscription to the Cue Weight Loss Program includes initial intake, prescription review, a personalized treatment plan, ongoing clinician support, and periodic at-home test kits for ongoing monitoring, which are shipped once every three months. Payment for subscriptions is collected at the beginning of each subscription term and refunds on program fees incurred before canceling are not available, even if it is determined that you are no longer eligible to participate in the program during the course of treatment. Periodic consultations are required every three months to evaluate whether prescription refills are appropriate, and you may also be required to obtain periodic lab testing for continued eligibility in the weight loss program. You will be able to also initiate on-demand consults to address any questions outside of the periodic consultations at your convenience; 2 on-demand consult credits will be included in your program every 6 months. Use of Cue’s at-home test kits is required for GLP-1 prescriptions. The discounted price reflects the first term of the program only. All renewals will be at the full price indicated. Your subscription will be auto-renewed until canceled per the Cue Terms of Use or as provided in this disclaimer. You may cancel your subscription to the program anytime before the next renewal term in the Cue Health App or by emailing support@cuehealth.com. The price of your test includes the costs for an independent physician or nurse practitioner to review your information, determine whether testing is appropriate, and provide follow-up on your results, plus fees for other administrative and operational support. Of the $99 monthly program fee, $10.00 is payable to Wheel Provider Group for its test review for each at-home test kit provided periodically, $48 is payable to Wheel Provider Group for the initial consultation, and $40 is payable to Wheel Provider Group for each subsequent follow-up or on-demand consultation.

To be eligible for treatment with a weight loss prescription medication, a patient must be aged 18 to 70 years, be reviewed by a medical professional, must have a BMI of 30 or above, or a BMI between 27 and 29.9 and at least one of the following conditions: type 2 diabetes, prediabetes, high blood pressure, high cholesterol, sleep apnea, or cardiovascular disease.

Every medication or treatment may have side effects, contraindications, interactions, or may not be effective for certain individuals. For a full and up-to-date list of medication information, including side effects, please search the medication at https://dailymed.nlm.nih.gov or review the medication guide that comes with the medication.

Medications subject to availability.

When completing your medical questionnaire for prescription approval, please disclose all allergies, medications and supplements you are currently taking, and other necessary medical information to help your healthcare provider determine the best dosage and treatment options for you.

Do not use GLP-1s (glucagon-like peptide-1 receptor agonists) if you or a member of your family has a history of medullary thyroid carcinoma (MTC) or if you have multiple endocrine neoplasia type 2 (MEN 2).

Most weight loss medications require prior authorization in order for insurance to cover the cost. Oftentimes, insurance will not cover GLP-1 medications if they are prescribed for weight loss.

Wegovy and Saxenda are FDA-approved as adjuncts to a reduced calorie diet and increased physical activity for chronic weight management in adults with obesity or with overweight and at least one weight-related comorbid condition, such as high blood pressure, type 2 diabetes, or high cholesterol. Ozempic and Mounjaro are FDA-approved as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes but may be prescribed for weight loss if deemed medically appropriate. Ozempic is also indicated to reduce the risk of major adverse cardiovascular events, such as non-fatal or fatal heart attack or stroke, in adults with type 2 diabetes and cardiovascular disease.

Due to state restrictions, this program is not available to residents of New York.